GlassScriptPhysician profile
Emily S Danver
NPI 1851819049
$1,895.73
in general payments reported to CMS, 2019-2025
24 companies · $708 in 2025
The $708 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $41.94 · 2023: $300 · 2024: $651 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,184 · Education: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,184.22 |
| Education | $475.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $394.40 | 2021-2025 | Xtandi |
| E.R. Squibb & Sons, L.L.C. | $206.83 | 2022-2025 | Opdivo |
| Janssen Biotech, INC. | $199.94 | 2023 | Rybrevant |
| Daiichi Sankyo INC. | $124.94 | 2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $113.39 | 2024-2025 | Keytruda, Lynparza, Reblozyl |
| Eisai INC. | $109.19 | 2023-2025 | |
| Lilly USA, LLC | $93.27 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Pfizer INC. | $85.46 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $71.84 | 2024-2025 | |
| Genzyme Corporation | $71.05 | 2024-2025 | |
| Exelixis INC. | $69.96 | 2024-2025 | Cabometyx |
| Incyte Corporation | $61.37 | 2024-2025 | Jakafi, Pemazyre, Monjuvi |
| Stemline Therapeutics INC. | $57.05 | 2024-2025 | Elzonris, Orserdu |
| Glaxosmithkline, LLC. | $37.86 | 2024-2025 | Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $30.90 | 2023-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $23.82 | 2025 | Epkinly |
| Genentech USA, INC. | $21.20 | 2025 | Tecentriq |
| Geron Corporation | $20.09 | 2025 | Rytelo |
| Servier Pharmaceuticals LLC | $20.04 | 2025 | |
| Taiho Oncology, INC. | $19.87 | 2024 | |
| Mirati Therapeutics, INC. | $16.92 | 2023 | Krazati |
| Adc Therapeutics America, INC. | $16.18 | 2024 | |
| Sumitomo Pharma America, INC. | $16.01 | 2024 | Orgovyx |
| Celgene Corporation | $14.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Danver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.